Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

Summary

This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Major Depressive Disorder (MDD)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 70 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Supernus Pharmaceuticals, Inc.

Last updated on ClinicalTrials.gov

October 28, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites